Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003388350 | SCV004099618 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-09-07 | criteria provided, single submitter | clinical testing | Variant summary: The variant identified by MLPA or other technology involves the deletion of exon 8 , the penultimate exon of the RAD51C gene. A presumed nomenclature of c.(965+1_966-1)_(1026+1_1027-1)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is expected to result a frameshift and premature truncation in the last exon in the RAD51C gene, but is not predicted to undergo nonsense mediated decay. The variant was absent in 21544 control chromosomes (gnomAD, structural variant dataset). c.(965+1_966-1)_(1026+1_1027-1)del has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (e.g. Slavin_2017, Lilyquist_2017, Yang_2020). These data indicate that the variant is likely associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. However, a splice variant that has been shown to result in the skipping of exon 8 (c.1026+5_1026+7delGTA) has also been observed in multiple individuals with HBOC and has been classified as pathogenic by our laboratory, suggesting that the last two exons of RAD51C are important for protein function. The following publications have been ascertained in the context of this evaluation (PMID: 28649662, 32107557, 28888541). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and both submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |